Data Linking Diabetes Mellitus and Atrial Fibrillation-How Strong Is the Evidence? From Epidemiology and Pathophysiology to Therapeutic Implications

Can J Cardiol. 2018 Nov;34(11):1492-1502. doi: 10.1016/j.cjca.2018.08.018. Epub 2018 Aug 16.

Abstract

According to estimates, around 5% of the world population has hazel eyes. And there are about as many people with diabetes mellitus (DM). Red hair occurs naturally in up to 2% of the human population. And about as many people are estimated to have atrial fibrillation (AF). If a hazel eyed person with red hair does not surprise us, should a diabetic patient with AF? Accumulating epidemiologic data suggest, however, that the DM-AF association may be more than a simple coincidence. But, how strong is this evidence? Experimental studies bring evidence for a DM-induced atrial proarrhythmic remodelling. But how relevant are these data for the clinical setting? In this review, we aim to provide a critical analysis of the existing clinical and experimental, epidemiologic, and mechanistic data that bridge DM and AF, we emphasize a number of questions that remain to be answered, and we identify hotspots for future research. The therapeutic implications of the DM-AF coexistence are also discussed, with a focus on rhythm control and on conventional and DM-specific upstream therapies for AF management.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Anti-Arrhythmia Agents / therapeutic use
  • Atrial Fibrillation / epidemiology
  • Atrial Fibrillation / physiopathology*
  • Atrial Fibrillation / therapy*
  • Atrial Remodeling / physiology
  • Autonomic Nervous System / physiopathology
  • Catheter Ablation
  • Comorbidity
  • Diabetes Mellitus / epidemiology
  • Diabetes Mellitus / physiopathology*
  • Diabetes Mellitus / therapy
  • Glycation End Products, Advanced / physiology
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Inflammation / physiopathology
  • Oxidative Stress / physiology
  • Risk Factors
  • Transcription Factors / physiology

Substances

  • Anti-Arrhythmia Agents
  • Glycation End Products, Advanced
  • Hypoglycemic Agents
  • Transcription Factors